SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anlon Healthcare develops two new anti-malarial products

20 Sep 2025 Evaluate

Anlon Healthcare has successfully developed two new anti-malarial products, Artemether and Lumefantrine. The company is expected to launch both products by November 2025. This development is in line with its strategy to expand the product portfolio and cater to the evolving needs of its clientele.

Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets.


Anlon Healthcare Share Price

14.07 0.88 (6.67%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×